Polaris宣布Chi Van Dang博士加入科學顧問委員會
聖地亞哥,2018年7月9日–專注於開發癌症新藥的生物製藥公司Polaris Group宣布,Ch …
聖地亞哥,2018年7月9日–專注於開發癌症新藥的生物製藥公司Polaris Group宣布,Ch …
SAN DIEGO, June 05, 2018 – Polaris Group, a biopharmaceutical company focused on developing novel drugs for cancer, announced results from a phase 1 clinical study that features Polaris lead therapeutic candidate ADI‑PEG 20 in combination with pemetrexed and cisplatin (ADIPEMCIS) in first-line treatment for argininosuccinate synthetase (ASS1) deficient metastatic uveal melanomas. The results were presented by Dr. Peter Szlosarek from Barts Cancer Center in the UK (abstract No.2589) at the American Society Clinical Oncology’s 2018 annual meeting.